Methods: A total of 77 cases of severe trauma 
INTRODUCTION
Disseminated intravascular coagulation (DIC) secondary to severe trauma, infection, and major surgery is a common fatal disease in the intensive care unit (ICU) [1] . At present, other than etiological treatments, hemostatic treatments that supply fibrinogen (Fg), plasma, and blood coagulation factors, as well as plaqueinactivation treatments that involve the infusion of
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unfractionated heparin (UFH), low-molecularweight heparin (LMWH), activated protein C, and antithrombin III (ATIII), are also popular treatments for DIC [2] .
However, the most common treatments that use UFH or LMWH are more likely to result in a fatal massive hemorrhage, which makes the practicability and safety of these treatments controversial [3] . Based on the results from a small-scale clinical research study [4] , we used low-dose UFH and LMWH to treat patients with traumatic DIC in the ICU from June 2007 to February 2010. In this study, the effects of anticoagulation treatments that alter ATIII levels in the blood were examined.
METHODS

Subjects
This research was carried out in accordance with the guidelines of the Declaration of Helsinki [5] and 
Experimental protocols
Patients were diagnosed with DIC using the ISTH scoring scale and evaluated every one or two days. Based on the inclusion and exclusion criteria, 77 patients were included in the study. All patients were treated using trauma control principles, including the administration of plasma and cryoprecipitates. Patients in the LMWH group were treated with an LMWH infusion, whereas patients in the UFH group were treated with an UFH infusion. The initial dose of LMWH (75 -150 units/kg/d) was 4,000 units/d, and the initial dose of UFH (100 -250 units/kg/d) was 5,000 IU/d; the amounts were adjusted based on patients' ATIII levels. When ATIII levels of patients in the LMWH group were lower than 60 %, 600 to 800 mL fresh-frozen plasma were transfused initially, and then 4,000 units LMWH were given by subcutaneous injection twice per day.
When ATIII levels were greater than 60 %, 4,000 units LMWH calcium were administered as the primary treatment, and plasma was then transfused, depending on the activated partial thromboplastin time (APTT) and Fg levels. When ATIII levels were greater than 80%, the amount of LMWH administered increased to 4,000 units twice per day. Meanwhile, when ATIII levels of patients in the UFH group were less than 60 %, 600 -800 mL fresh-frozen plasma were transfused initially, and 5,000 units UFH were later administered by subcutaneous injection. When ATIII levels were greater than 60 %, the amount of infused plasma was determined based on the APTT and Fg levels after transfusing 5,000 units UFH.
When ATIII levels were greater than 80 %, the amount of UFH was increased to 10,000 units per day. In the control group, when ATIII levels of patients were lower than 60 %, 600 -800 mL fresh-frozen plasma were transfused. When ATIII levels were greater than 60 %, the amount of plasma was determined based on the APTT and Fg levels. However, once the anticoagulation treatment caused longer APTTs and hemorrhages in patients, the patients in the LMWH group were treated with fresh-frozen plasma, while patients in the UFH group received equal amounts of protamine to counteract the function of the heparin. All treatments were stopped when the thrombin time (TT), prothrombin time (PT), APTT, and Fg levels normalized.
Treatment indices
In the present study, the following indices were evaluated: 1) DIC score utilizing ISTH guidelines; 2) incidence of death within 28 days, TT, PT, APTT, and levels of Fg, ATIII, and D-dimer, and length of hospital stay (two senior ICU doctors concurred on a diagnosis of DIC, the time of death, and discharge from the ICU); 3) hemorrhage rate within 28 days; and 4) indices of relative risk (RR), relative risk reduction (RRR), and absolute risk reduction (ARR).
Statistical analysis
Using SPSS 11.0 software for the analyses, the results are expressed as mean± SD, and data were compared using analysis of variance. P < 0.05 was considered statistically significant. 
RESULTS
Incidence of death in the three groups
Length of stay in the ICU
There were statistical differences in the lengths of stay in the ICU among the three groups, as shown by the log-rank analysis method. The X 2 value was 20.29 (p < 0.01). The area under the Kaplan-Meier curve (Figure 1 ) revealed that the length of stay in the ICU of the control group was shorter than in both the LMWH and UFH groups, the death incidence was higher (p < 0.01), and the length of stay in the ICU of the LMWH group was longer than in the UFH group.
DIC score and PT, APTT, TT, and levels of ATIII, D-dimer, and Fg
The DIC scores and PT, APTT, TT, and levels of ATIII, D-dimer, and Fg are shown in Tables 1 and  2 . APTT and TT reflect the range between standard and actual times. 
Incidence of hemorrhage
During the study duration, 16 patients experienced hemorrhages in the LMWH group (61.5 %), 8 patients experienced hemorrhages in the UFH group (32 %), and 22 patients experienced hemorrhages in the control group (84.6 %). The differences in the incidence of hemorrhage between the control group and the LMWH group, and between the LMWH group and the UFH group, were not statistically significant (X 2 = 3.519, P > 0.05); however, the difference in the incidence of hemorrhage between the UFH group and the control group was statistically significant (X 2 = 14.567, p > 0.05). The incidence of hemorrhage in the UFH group was lower than that in the LMWH and control groups, and the difference in the incidence of hemorrhage between the LMWH and control groups were not statistically significant.
Correlation between the incidence of hemorrhage and ATIII levels
The rate of logistic regression, which assumes that the incidence of hemorrhage is a dependent variable, was 81.3%, with only ATIII levels, PT, and a grouping variable applied to the model. The difference between ATIII levels appears to be statistically significant (OR = 0.931, p < 0.01). As the amount of ATIII increased by one unit, the incidence of hemorrhage decreased about 7 %. The difference in PTs was not statistically significant, which means that the predictive accuracy of the incidence of hemorrhage was not high.
DISCUSSION
Direct severe trauma and secondary low perfusion shock are the primary causative factors of DIC [7] . Severe trauma and surgical interventions can induce a coagulation reaction between tissue factors and factor VII that can excessively activate the coagulation pathway and lead to the massive production of coagulation factors. Additionally, the amount of tissue plasminogen released by endothelial cells, stimulated by thrombin after trauma, increases, inhibiting excessive blood clot formation. Overstimulation of the coagulation and fibrinolysis reactions can result in DIC, which has high rates of both hemorrhage and death [8] .
To prevent the "death triad" in severe trauma patients (low body temperature, coagulation disorders, and severe acidosis), internal bleeding must be controlled quickly, necrotic tissues must be resected, and traumatic injuries must be controlled according to trauma control principles. Additionally, ICU doctors typically further prevent the death triad by restoring the patient's normal physiological functions [9] . Therefore, anticoagulant treatment should be used to address traumatic DIC. However, technology and patent limitations, abnormal ATIII levels, and activated protein deficiency make UFH and LMWH the most common treatments for DIC and an increased topic of interest in clinical research [10] .
The interaction between heparin and ATIII allows heparin to exert its anticoagulant effects: Heparin binds the δ-amino group of a lysine residue in ATIII to accelerate the inactivation of coagulation factors IIa, IXa, Xa, Xia, and XIIa, resulting in the inhibition of thrombokinase, XIII activation, and fibrous protein formation. In addition, heparin can also negatively regulate the activation of factors VII and V, which causes platelet aggregation and destruction, inhibiting coagulation [11] . Common heparin is useful in hypercoagulable phages, which continuously reduce the levels of platelets and coagulation factors, as well as the time of microembolization.
In consumed hypercoagulable phages, common heparin can be used with coagulation factors to alleviate DIC when the source of the pathogenesis cannot be addressed quickly [12] .
In this study, the results showed that ATIII levels decreased by 50 %, lowering the effects of heparin and increasing the incidence of hemorrhage, in accordance with results observed in other types of DIC [13] . To overcome these sequelae, studies have begun to focus on LMWH as a treatment. In vitro, LMWH can quickly antagonize factor X activity during blood clot formation without altering blood coagulation and platelet function. Furthermore, the dose-effect relationship of LMWH is stable because of its low molecular weight and long half-life. Some researchers have demonstrated that the difference between LMWH and UFH is not statistically significant in patients with DIC caused by acute promyelocytic leukemia, suggesting that both have equally curative effects [14] . However, LMWH causes a lower incidence of hemorrhage.
The observation time, 28 days, is in accordance with the criteria for assessing fatal DIC [15, 16] . Based on the specificity and high incidence of death from traumatic DIC in ICU patients, we utilized small doses of LMWH (75 -150 units/kg/d, depending on ATIII levels, with a primary dose of 4,000 units/d) and UFH (100 -250 units/kg/d, depending on ATIII levels, with a primary dose of 5,000 IU/d,) [11, 17] . The incidence of death in the LMWH and UFH groups was lower than that in the control group, and survival time in the ICU was longer in the LMWH and UFH groups than in the control group. Additionally, the UFH group had a shorter discharge time and lower incidence of hemorrhage than the LMWH group, but the death rates were the same between these two groups [18] . Although more large-scale studies are needed, the results of this study showed that low doses of UFH can be used to treat traumatic DIC.
In this study, the differences in ATIII levels among the three groups were significant, as demonstrated by one-way analysis of variance, suggesting that low doses of both UFH and LMWH can increase ATIII levels, regulate the anticoagulation reaction, and decrease the incidences of hemorrhage and death, similar to supplementation with coagulation factors. Related analyses of coagulation factors have also yielded similar results. As ATIII levels decrease, the incidence of hemorrhage increases, which may serve as an indication for adjusting the UFH or LMWH dose to resolve the problem. Therefore, ATIII levels can be used to adjust the dose of heparin. Although the dose of LMWH can be regulated by determining the patient's weight, the results of this study do not show a statistical benefit from the use of LMWH.
CONCLUSION
Methods based on the trauma control principle (e.g., rescuing supplemental coagulation factors and applying low doses of heparin) help treat DIC. Regulating heparin dose based on ATIII levels can lower the incidences of both hemorrhage and death. In addition, although both the correlation of ATIII levels with the incidence of hemorrhage and the curative effects of the different forms of heparin were not statistically significant, a heparin dose-adjusting strategy may still yield treatment benefits.
